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Summary
Using a mouse model of human acute myeloid leukemia (AML) induced by the MLL-AF9 oncogene, we demonstrate that
colony-forming cells (CFCs) in the bone marrow and spleen of leukemic mice are also leukemia stem cells (LSCs). These
self-renewing cells (1) are frequent, accounting for 25%–30% of myeloid lineage cells at late-stage disease; (2) generate
a phenotypic, morphologic, and functional leukemia cell hierarchy; (3) express mature myeloid lineage-specific antigens;
and (4) exhibit altered microenvironmental interactions by comparison with the oncogene-immortalized CFCs that initiated
the disease. Therefore, the LSCs responsible for sustaining, expanding, and regenerating MLL-AF9 AML are downstream
myeloid lineage cells, which have acquired an aberrant Hox-associated self-renewal program as well as other biologic
features of hematopoietic stem cells.Introduction
Acute myeloid leukemia (AML) is a clonal neoplastic disorder
that originates from a single transformed cell, which has pro-
gressively acquired critical genetic or epigenetic changes that
disrupt key growth-regulatory pathways (Hanahan and Wein-
berg, 2000). Within the leukemia clone, there is significant cellu-
lar morphologic, phenotypic, and functional heterogeneity anal-
ogous to the hierarchical organization of normal hematopoiesis.
Notably, only a subfraction of cells are proposed to be leukemia
stem cells (LSCs) with the ability to self-renew extensively, and
to initiate, sustain, or regenerate the disease. Conversely, the
majority of cells are either transitional cells with limited prolifer-
ative capacity or more differentiated end cells (Mackillop et al.,
1983; Kummermehr, 2001). Evidence for a hierarchical cellular
organization of human AML derives from studies showing that
only a small proportion of AML cells are clonogenic in in vitro
culture (Buick et al., 1977), and that an even smaller fraction of
AML blood blasts, defined by a CD34+ CD382 surface pheno-
type, can transfer disease to immune-deficient mice (Lapidot
et al., 1994; Bonnet and Dick, 1997). Since normal human hema-
topoietic stem cells (HSCs) are also CD34+ CD382, these and
other observations (Miyamoto et al., 2000; Hope et al., 2003)
have been taken to suggest that AML LSCs originate from and
reside exclusively within the most immature bone marrow
(BM) progenitor compartment. However, this lineal relationship,CANCER CELL 10, 257–268, OCTOBER 2006 ª2006 ELSEVIER INC. DOIwhich has important pathogenic and clinical implications, may
not always hold true. For example, a recent study of blastic
transformation of chronic myeloid leukemia proposed that cells
with a granulocyte-macrophage progenitor (GMP) cell pheno-
type were candidate LSCs (Jamieson et al., 2004).
Elimination of the LSC compartment within the leukemia clone
is likely to be essential, and probably sufficient, for cure of dis-
ease, and thus increasing efforts have focused on attempting
to define the unique biological properties of AML LSCs by com-
parison with the transit and end cell compartments within the
leukemia, as well as with normal hematopoietic stem and pro-
genitor cells. However, an essential prerequisite for defining
these unique properties, so that targeted chemo- and immuno-
therapeutic strategies may be developed, is an accurate deter-
mination of the phenotype as well as the frequency of LSCs
within the AML clone. To date, such efforts have primarily
focused on xenografting human leukemia cells into immune-
deficient mice. A complementary, but currently unexploited,
approach is to characterize LSCs in mouse genetic models of
human leukemia, which have proven to be invaluable tools in
defining the mechanisms of disease pathogenesis. Two recent
studies have demonstrated that AMLmaybe initiated by expres-
sion of MLL-ENL or MOZ-TIF2 in progenitor cells with limited
self-renewal capacity, as well as in HSCs (Cozzio et al., 2003;
Huntly et al., 2004). However, these studies did not address
the critical issue of whether the respective murine leukemiasS I G N I F I C A N C E
An essential prerequisite for the development of more effective targeted therapies in AML is a characterization of the frequency and
biological properties of LSCs. In amousemodel of humanMLL-AF9 AML, we have defined the size and lineal derivation of the LSC com-
partment, the extent of whichwas significantly underestimatedby limit dilution analysis. Our findings support a revision of the prevailing
hypothesis that AML LSCs are always rare and solely located within the most immature bone marrow stem/progenitor compartment.
Furthermore, LSCs exhibit markedly different microenvironmental interactions, compared with cells simply immortalized by MLL-AF9,
indicating that acquisition of sensitivity to stromal cell-derived survival and proliferative signals is a critical feature of LSCs, in addition
to their extensive self-renewal capabilities.10.1016/j.ccr.2006.08.020 257
A R T I C L EFigure 1. MLL-AF9-immortalized CFCs have high
leukemogenic potential
A: Schematic illustration of the experimental
approach employed to assess the correlation
of leukemogenic potential with CFC activity of
MLL-AF9-immortalized cells. BM stem and pro-
genitor cells (c-kit+) were transduced with MLL-
AF9 and then serially replated in methylcellulose
medium every 5 days, with G418 drug selection
in the first round. Single colonies (33 total over
five experiments) with either type I (16 each) or
type II (17 each) morphology (Lavau et al.,
1997) were plucked and individually expanded
in liquid (29) or semisolid (4) medium, and 106
cells were then transplanted into syngeneic re-
cipient mice. Single CFCs routinely expanded
to 106 progeny cells within 12–15 days.
B: The mean (6SEM) number of colonies (R1000
cells) per 10,000 cells plated in each round is indi-
cated. The clonogenic potential of progenitors
transduced with empty vector was exhausted
by the end of round two (data not shown). The
mean (6SEM) frequency of CFCs at the time of
transplant in the 14 lines derived from single
plucked colonies is indicated in the last column
(Tx).
C: Southern blot analysis (left panel) demon-
strates the integration sites in 14 separate trans-
planted lines derived from single immortalized
CFCs (neo probe of Stu1-digested genomic
DNA). A median of three integration sites per
clone is observed. Comparison of the integration
sites (right panel) in three representative paired
transplanted lines (L) with their respective AML
cells (A) confirmed that they were clonally
identical.
D: Survival curve of animals transplanted with
cells (106) derived from single MLL-AF9-immortal-
ized CFCs.
E: Representative cytospin of splenocytes (May
Grunwald Giemsa stain) from a mouse with
MLL-AF9 AML.were sustained by a small fraction of self-renewing Lin2 stem
and/or progenitor cells, as predicted by current models of AML
based on NOD/SCID transplantation assays, or alternatively,
whether the LSC compartment is larger and altogether distinct
from the normal stem and progenitor compartment.
We report here the identification and characterization of LSCs
in a mouse model of AML initiated by MLL-AF9, a frequently
occurring MLL fusion oncogene typically associated with the
FAB-M4 or M5 subtypes of human AML (Swansbury et al.,
1998). Our studies indicate that LSCs are neither rare nor synon-
ymous with the stem and progenitor cells targeted by initiating
MLLmutations. Rather, LSCs in this model are frequent, located
almost exclusively downstream of the normal progenitor com-
partment by immunophenotype, and constitute myeloid lineage
cells that have acquired an aberrant self-renewal program as
well as other biologic features of HSCs, including substantially
altered microenvironmental interactions.
Results
MLL-AF9-immortalized colony-forming cells display high
leukemia-initiating potential
The leukemogenic potential of single MLL-AF9-immortalized
colony-forming cells (CFCs) was evaluated using a retroviral
transduction/transplantation assay that reproducibly reads out258the properties of MLL fusion oncogenes (Lavau et al., 1997).
BM stem and progenitor cells (c-kit+) from EGFP transgenic
mice were transduced with MLL-AF9 and serially replated in
semisolid medium (Figures 1A and 1B). At the end of the third
round of culture, individual colonies were isolated and ex-
panded further in either liquid or semisolid media (Figure 1A).
Fourteen lines (representative of ten unique clones) (Figure 1C)
were randomly selected and injected (106 cells) into separate
sublethally irradiated, wild-type recipients. All mice developed
AML, with amedian latency of 84.5 days (range 60–121) (Figures
1D and 1E; Tables S1 and S2 in the Supplemental Data available
with this article online). Southern blot analysis demonstrated
that each leukemia was clonally identical to its respective in-
jected cell population (Figure 1C). Therefore, immortalized
colony-forming cells (ICs) transformed by MLL-AF9 in vitro con-
sistently possess the potential to initiate leukemias in vivo, dem-
onstrating a high correlation of CFC activity with leukemogenic
potential in this model of AML.
LSCs are frequent in mice with MLL-AF9 myeloid
leukemia
A similar approach was employed to analyze the leukemogenic
potential of CFCs derived from leukemic mice (Figure 2A).
Using semisolid culture assays, the CFC frequencies in the
BM and spleens of leukemic mice were 29.8% 6 4.1% andCANCER CELL OCTOBER 2006
A R T I C L E25.7% 6 3.3%, respectively, as a proportion of all myeloid line-
age cells (Figure 2B). To confirm that individual CFCs from
leukemic mice were also LSCs, defined here as cells with the
potential to transplant leukemia from one syngeneic host to an-
other, single colonies (16 total derived from three separate do-
nors) were randomly selected, plucked from culture, and directly
injected into syngeneic recipients without further in vitro manip-
ulation. All recipient mice succumbed to short latency AML (Fig-
ure 2C), and the resultant disease could be serially transplanted
to tertiary recipients using identical methodology (Figure 2C).
Similar results regarding leukemic CFC frequency, and the cells’
potential to transplant disease, were obtained regardless of
whether AML was initiated by transplantation of cells derived
from serially replated CFCs (Figure 1A) or transplantation of c-
kit+ stem and progenitor cells immediately following retroviral
transduction (data not shown). Therefore, the CFCs derived from
mice with MLL-AF9 leukemia are LSCs. Based on these criteria,
LSCs are present at a frequency of approximately 25%–30%
of myeloid lineage cells in the BM and spleen of leukemic mice.
MLL-AF9 LSCs express myeloid lineage-specific
antigens and are downstream of the normal progenitor
compartment by immunophenotype
To more precisely define LSCs with respect to their phenotype
and lineal origin, FACS analyseswere performed on splenocytes
Figure 2. LSCs are frequent in mice with MLL-AF9 leukemia
A: Schematic illustration of the experimental approach for determining the
correlation between clonogenic and leukemogenic potentials of single
MLL-AF9 myeloid leukemia CFCs. Spleen or BM cells from leukemic mice
(1) were plated in semisolid medium. After culture for 7 days, single colonies
(typically 104 cells) were plucked, washed once in PBS/EDTA, and then
directly injected into sublethally irradiated, syngeneic recipients (2) (16 col-
onies in total transplanted from three separate donors). The process was
repeated using tertiary recipients (3) (six colonies from one donor).
B: Bar graph indicates the mean (6SEM) number of colonies (R1000 cells)
after 5 days of culture per 10,000 plated spleen or BM myeloid lineage cells
explanted from leukemic mice. The proportion of myeloid lineage cells in
the spleen and BM was determined by examination of MGG-stained cyto-
spins and confirmed by flow cytometry.
C: Representative survival curves of sublethally irradiated mice transplanted
with single AML colonies. Single AML colonies (n = 7) from an animal with
disease latency of 60 days were plucked after 7 days semisolid culture
and directly injected into secondary recipients (i). Similarly, single AML
CFCs (n = 6) from one of the secondarily transplanted mice (disease latency
36 days; splenic AML CFC frequency 27.2%) were plucked and injected to
confirm the ability of AML CFCs to serially transplant disease (ii).CANCER CELL OCTOBER 2006from leukemic mice. Almost all EGFP+ donor cells expressed
Mac1 and/or Gr1, while somewhat lower percentages of cells
expressed c-kit, FcgII/IIIR, CD24, Pecam1, CD34, and/or F4/80
(Figure 3A and Table 1). Leukemia cells consistently lacked
expression of the stem cell antigen Sca1, the cytokine receptor
Flt3, or markers specific for the lymphoid (B220, IgMa, CD3,
TCRb), megakaryocytic (CD41), or erythroid (TER119) lineages
(Table 1). A similar phenotype was displayed by the expanded,
immortalized cell populations, which originated from single
MLL-AF9 ICs in vitro (data not shown). Since approximately
26% of EGFP+ splenocytes were LSCs, the near-uniform ex-
pression of Mac1 indicated that LSCs express myeloid line-
age-specific antigens. Further support for this conclusion was
provided by FACS sorting of leukemic splenocytes based on
surface marker coexpression, which revealed that 91.3% 6
3.8%of splenic LSC activity was present in theMac1+Gr1+ frac-
tion (Figure 3B) and 51.9% 6 29.0% was present in the Mac1+
F4/80+ fraction (Table 1). Furthermore, animals secondarily
transplanted with leukemic splenocytes (20–100,000) sorted
for Gr1 expression died of AML with a median latency of 28
days (range 24–38 days; n = 5). Similarly, all mice secondarily
transplanted with single plucked colonies derived from spleno-
cytes sorted for coexpression of c-kit, Gr1, and F4/80 died of
AML with a median latency of 44 days (range 44–52; n = 5).
Thus, MLL-AF9 LSCs express lineage-specific antigens most
consistent with a relatively late-stage myeloid phenotype, sug-
gestive of maturational arrest distal to the GMP.
MLL-AF9 LSCs are not enriched in the normal stem
and progenitor compartments
Rare EGFP+ splenocytes (0.11%6 0.06%; n = 9) lacked expres-
sion of lineage-specific antigens (Figure 3C). Since the Lin2
compartment harbors normal stem and progenitor cells, Lin2
EGFP+ cells were analyzed for expression of antigens that
mark normal HSCs. None of the cells displayed a c-kit+ Sca1+
Lin2 (KSL) immunophenotype (Figure 3C; n = 6), indicating
that no donor-derived cells were present in the normal HSC
compartment. By contrast, cells with a KSL immunophenotype
were clearly detected in the EGFP2 Lin2 splenocyte population,
consistent with the presence of residual, recipient origin, normal
hematopoiesis in the leukemic mice (Figure 3C). FACS sorting
and in vitro culture of the rare EGFP+ c-kit+ Sca12 Lin2 cells
from leukemic mice produced a lower mean CFC frequency
(8.5% 6 8.3%; n = 3) than that found in the Lin+ fraction.
Thus, there was no enrichment of LSCswithin the Lin2 compart-
ment, and indeed, when the absolute numbers of CFCs with
a Lin+ phenotype were considered, it was clear that the over-
whelming majority (>99.8%) of CFCs, and therefore LSCs, re-
sided by immunophenotype downstream of the normal progen-
itor hierarchy (Figure 3B). Similar AML CFC frequencies (4.4%6
4.2%; n = 4) were found in FACS-sorted Lin2 splenocytes from
leukemicmicewhere diseasewas initiated using c-kit+ stem and
progenitor cells transplanted immediately following retroviral
transduction, and likewise 99.9% of the CFC/LSCs had a Lin+
phenotype.
MLL-AF9 LSCs establish a leukemia cell hierarchy
A subset of cells in each leukemia expressed c-kit, a surface an-
tigen expressed highly by normal BM stem and progenitor cells.
To determine if c-kit expression specificallymarks the LSC com-
partment in MLL-AF9 AML, EGFP+ spleen cells from leukemic259
A R T I C L EFigure 3. MLL-AF9 LSCs and ICs express myeloid
lineage-specific antigens
A: Representative FACS profiles of splenocytes
from a mouse with MLL-AF9 AML. Almost all of
the donor (EGFP+)-derived cells (left panel)
express the myeloid antigens Gr1 and/or Mac1
(right panel).
B: Pie chart shows the percentage of LSCs in the
indicated immunophenotypic fractions. Clono-
genic cell frequencies for each immunopheno-
type were determined by culture of FACS-sorted
EGFP+ AML splenocytes (n = 4 animals). The pro-
portion of total LSCs located in each fraction
was determined as the percentage of cells
with a specific immunophenotype times the
CFC frequency for that immunophenotype.
C: Representative c-kit+/Sca1+/Lin2 (KSL) FACS
profiles of splenocytes from a mouse with MLL-
AF9 AML. A very small fraction (less than 4 in
100,000) of donor (EGFP+) cells in this example
are Lin2, and all lack a KSL immunophenotype
(II). Rare cells are present in the progenitor
gate (c-kit+ Sca12). In contrast, EGFP2 Lin2 recip-
ient splenocytes demonstrate a typical progeni-
tor cell and KSL immunophenotype (I).mice were double flow-sorted into c-kit-positive and -negative
fractions (Figure 4A). The c-kit+ populations contained a higher
proportion of cells with cytologic features of blasts (Figure 4B),
displayed a 14.2-fold higher proportion of CFCs (Figure 4C),
and induced death from AML significantly more rapidly in sec-
ondarily transplanted recipients (Figure 4D). LSC-enriched (c-
kit+) cells induced AML that fully recapitulated the pathologic,
morphologic, and phenotypic features of the original disease
(data not shown). Quantitative PCR analysis demonstrated sig-
nificant downregulation of several Hoxa genes and upregulation
of the cell cycle inhibitorsCdkn2a andCdkn2c in c-kit2 versus c-
kit+ populations (Figure 4E). Further cell sorting experiments
demonstrated no substantial differences in the clonogenic po-
tentials of cells based on the presence or absence of expression
of Pecam1, CD24, CD34, FcgII/IIIR, Gr1, or F4/80 (Table 1).
These results indicated that LSCs were highly enriched, but
not exclusively contained, within the c-kit+ fraction. LSCs in
this model of AML are not distinguished by a specific immuno-
phenotype. However, the distinctive morphologic, clonogenic,
transcriptional, and transplant properties of cells differentially
expressing c-kit demonstrate a loose hierarchical organization
of the AML clone. Furthermore, the LSC-containing apex of
the hierarchy is broad (based on 25%–30% AML CFC fre-
quency), but almost entirely outside of the normal progenitor
compartment, and extends into the c-kit-negative leukemia
cell population.
MLL-AF9 LSCs are aberrantly self-renewing myeloid
lineage cells, as opposed to HSCs, which ectopically
express myeloid lineage antigens
Further comparative transcriptional profiling analyses were per-
formed on c-kit+ and c-kit2 leukemia cell populations as well
as sorted normal stem and progenitor cell populations. c-kit+
leukemia cell populations containing a high proportion of LSCs
expressed moderate to high levels of genes (Ela2, Prtn3, and
Gstm2) normally expressed in committed myeloid lineage cells,
versus low levels of genes (Flt3 and Mpl) normally expressed
highly by stem cells or multipotent progenitors (Figure 5) (Ter-
skikh et al., 2003). Consistent with the presence of an aberrant260MLL-AF9-driven self-renewal program in LSCs, most Hoxa
genes were expressed at levels equal to or greater than those
in normal stem and multipotent progenitor cells (Figure 5).
Thus, the transcriptional profiles and immunophenotypes of
MLL-AF9 LSCs, in addition to their lack of multilineage differen-
tiation potential (Table 1), are characteristic of aberrantly self-
renewing downstream myeloid lineage cells and not HSCs
ectopically expressing myeloid lineage antigens.
Enhanced engraftment potential qualitatively
distinguishes MLL-AF9 LSCs from ICs
The foregoing studies demonstrated a high correlation of CFC
and leukemia-initiating potential for both ICs and LSCs (Figures
1 and 2). However, further transplant studies indicated that, at
an equivalent cell dose (106), cells derived from single ICs in-
duced AML with a 3- to 4-fold longer latency than cells derived
from single LSCs (median 27 versus 100 days, respectively; sur-
vival curves not shown). The differences in leukemic potential
were confirmed by limit-dilution transplant studies, which re-
vealed that the predicted mean dose of ICs required to initiate
AML was 66,300, whereas the required number of AML spleno-
cytes was 121 (Figure 6A). Since CFC frequencies were broadly
similar in the IC and LSC populations, the results strongly sug-
gested that ICs are qualitatively different andmust acquire addi-
tional functional properties in vivo to become fully competent
LSCs.
Further transplant studies were conducted to investigate
whether the qualitative differences in leukemic potential resulted
from differential homing and/or engraftment. Paired IC and LSC
populations clonally derived from a single IC were directly com-
pared for these and all subsequent analyses. Twenty-four hours
following transplantation of syngeneic mice, comparably small
proportions of the injected ICs (0.34% 6 0.16%) and LSCs
(0.05% 6 0.006%) were located in the BM (p = 0.16; n = 4)
and spleen (0.03% 6 0.008% versus 0.005% 6 0.002%, re-
spectively; p = 0.10; n = 4) (Figure 6B). These data indicated
that both cell populations were markedly inefficient in homing
following transplantation and thus did not account for the en-
hanced leukemic potential of LSCs compared to ICs. However,CANCER CELL OCTOBER 2006
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present in the BM had increased 5900-fold, versus only a 5-
fold increase for IC progeny (Figure 6B). Similar divergent fold in-
creases were observed in the spleen (895 versus 0.5). At day 20
posttransplant, mice that received LSC-derived cells contained
approximately 200- and 3700-fold more EGFP+ cells in their BM
and spleens, respectively, compared with those that received
IC-derived cells. Therefore, despite similarly poor BM homing
of the respective populations, LSCs were much more efficient
at proliferating and generating progeny (i.e., engrafting) after
homing. Taken together with the limit dilution analyses, these
data confirm that acquisition of enhanced engraftment potential
is a key step in the progression of ICs to LSCs.
MLL-AF9 LSCs display increased sensitivity
to stroma-derived proliferation signals
To investigate whether growth factor sensitivities may underlie
the engraftment differences of MLL-AF9 LSCs versus ICs,
paired cell populations were cultured in medium containing
single cytokines. No significant differences in proliferation be-
tween the populations were observed when cells were cultured
in either interleukin-3 (IL-3) or granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Figure 6C). However, when cul-
tured in interleukin-6 (IL-6), interleukin-11 (IL-11), stem cell fac-
tor (SCF), or Flt ligand (FL) alone, LSC-containing populations
frequently displayed an acquired ability to proliferate by com-
parison with their corresponding IC-containing populations
Table 1. Phenotypic features correlated with clonogenic properties of
MLL-AF9 LSC populations











Mac1/CD11b 97.6 6 0.6 ND ND
Gr1/Ly6G 85.8 6 2.8 91.3 6 3.8 (n = 4) 8.7 6 3.8
c-kit/CD117 54.1 6 6.4 93.4 6 3.0 (n = 6) 6.6 6 3.0
FcgRII/III/CD16/32 76.2 6 3.1 67.7 (n = 1) 32.3
CD34 56.2 6 10.6 52.3 6 43.4 (n = 2) 47.7 6 43.3
CD24 53.3 6 8.4 13.1 (n = 1) 86.9
Pecam1/CD31 70.7 6 5.8 64.6 6 1.2 (n = 2) 35.4 6 1.2
F4/80 23.8 6 8.2 51.9 6 29.0 (n = 2) 48.1 6 29.0
Flt3/CD135 0 NA NA
Sca1 0 NA NA
B220 0 NA NA
IgMa 0 NA NA
CD3 0 NA NA
TCRb 0 NA NA
CD41 0 NA NA
TER119 0 NA NA
NA, not applicable. ND, not determined, because infrequent Mac1-nega-
tive cells were almost always Gr1 positive (see Figure 3A). See text for
data on Lin2 cells.
aEGFP+ splenocytes from mice with AML were analyzed for the indicated
antigens by FACS. Dead cells were excluded from analysis using propidium
iodide staining.
bEGFP+ splenocytes from a subset of animals with AML were additionally
FACS sorted for the presence or absence of expression of the indicated an-
tigens, and then cultured for 6 days in methylcellulose to determine the CFC
frequency (data not shown) in each fraction. The percentage of clono-
genic cells in the positive (column 3) versus negative (column 4) immuno-
phenotypic fractions for each marker was then determined by multiplying
the CFC frequency for each immunophenotype by the percentage of cells
with that immunophenotype (column 2).CANCER CELL OCTOBER 2006(Figure 6D). Additionally, LSC-containing populations tolerated
growth factor withdrawal for 5 days in significantly higher num-
bers (Figure 6E, columns 1 and 4; p < 0.05).
The observed growth factor sensitivities acquired by LSCs
suggested an enhanced ability to derive survival and prolifera-
tion signals from stromal cells, which secrete IL-6 and IL-11.
When cultured on an S17 stromal cell layer, LSC-containing
populations proliferated significantly more rapidly than IC popu-
lations in a 5 day assay (3.0- 6 0.4-fold expansion compared
with 1.46 0.2; p = 0.005) (Figure 6E). Similarly, LSC populations
cocultured for 5 days on OP9 stroma were on average 7.2-fold
more abundant than IC populations (p = 0.003) (Figure 6E). Ex-
periments using stroma-conditioned medium indicated that
secreted factors accounted for only a portion of the stroma-
derived survival/proliferation signal (Figure 6E). Therefore, an
improved ability to survive/proliferate in response to stroma-
derived signals, both secreted and contact-mediated, is a criti-
cal feature that distinguishesMLL-AF9 LSC from IC populations.
AML LSCs demonstrate increased chemotaxis to SDF1
and express higher levels of activated Rac and Cdc42
Normal HSC engraftment is critically dependent on SDF1/
CXCR4 and Rac1 signaling (Peled et al., 1999; Gu et al., 2003)
and correlates with the ability to undergo SDF1-induced chemo-
taxis (Peled et al., 1999). LSC populations exhibited significantly
increased Cxcl12 (SDF1)-induced chemotaxis by comparison
with their paired IC populations (Figure 7A), and this was not
due to differential adhesion properties (Figure 7A), nor increased
expression of Cxcr4, as estimated by FACS mean fluorescence
intensity (Figure 7B). Expression levels of small GTPases, which
are critical mediators of cell migration and engraftment, showed
a small, but consistent, significant increase in Cdc42 (Figure 7C)
and a greater, but more variable, increase in Rac in LSC by com-
parison with paired IC populations. Levels of Cdc42-GTP and
Rac-GTP were also elevated. Therefore, progression of MLL-
immortalized cells to LSCs is accompanied by several features
associated with enhanced engraftment potential, including in-
creased survival/proliferative abilities in contact with stromal
cells, increased SDF1 induced chemotaxis, and elevated ex-
pression of small GTPases.
Discussion
Wehave identified and characterized LSCs in a somatic, genetic
mouse model of leukemia that faithfully recapitulates many of
the pathologic and clinical attributes of human AML initiated
by MLL oncogenes. Unexpectedly, we found that the LSC com-
partment is relatively large, lineage-positive, and positioned
phenotypically almost entirely downstream of the GMP. There-
fore, the LSCs responsible for sustaining AML in this model
are not synonymous with the stem and progenitor cells initially
targeted by MLL oncogenes. Nevertheless, LSCs share several
genetic and functional features of HSCs, including a self-
renewal transcriptional program of high Hox gene expression.
They also display a wide range of hematopoietic growth factor
sensitivities, increased SDF1-induced chemotaxis, and an
enhanced ability to interact with BM stromal cells, all of which
are also biologic attributes shared with HSCs. These features
likely explain the observed substantial enhancement of LSC
engraftment potential in transplantation assays by comparison
with ICs. Thus, LSCs in MLL-AF9 AML are downstream myeloid261
A R T I C L EFigure 4. Phenotypic, morphologic, and functional evidence of a cellular hierarchy in MLL-AF9 leukemia
A: FACS analyses demonstrate c-kit expression on fresh splenocytes from mice with AML prior to (Pre-sort) and after (Post double sort) double flow sorting into
c-kit-positive and c-kit-negative fractions.
B: Splenocytes from leukemic mice were sorted based on their expression of c-kit and analyzed for the proportion of cells with morphologic features of blasts
versus differentiation following May Grunwald Giemsa staining of cytospin preparations. Bar graph indicates the mean (6SEM) number of cells with the indi-
cated morphologic and phenotypic features (n = 4).
C: Pie chart shows the percentage of clonogenic cells residing within the c-kit+ versus c-kit2 fractions of EGFP+ leukemic cells (n = 6). FACS-sorted leukemic
splenocytes were cultured in methylcellulose medium for 6 days to determine the CFC frequencies in each fraction (29.2% 6 3.5% and 5.4% 6 2.0%, respec-
tively; p < 0.001).
D: Bar graph indicates an average 25% shorter survival across varying cell doses for mice secondarily transplanted with c-kit+ AML cells versus recipients of
equivalent numbers of c-kit2 cells. Disease latencies shown are the means of two separate experiments using sorted cells from separate donor animals
with AML, one recipient animal per indicated cell dose. The numbers of transplanted cells are indicated on the left (k = 1000).
E: Bar graph indicates the change in expression levels of the indicated transcripts in sorted populations of EGFP+ c-kit2 leukemic splenocytes by comparison
with EGFP+ c-kit+ leukemic splenocytes (mean 6 SEM; n = 5). All transcript levels were normalized to levels of Actb expression using DCt methodology.lineage cells that have aberrantly acquired both genetic and
biologic features of HSCs.
The high frequency of LSCs in MLL-AF9 AML
is significantly underestimated by assays
dependent on engraftment
The estimated frequency of cancer stem cells in murine tumors,
as determined by limit dilution experiments, has been reported
to vary widely depending on the tumor type (Hewitt et al.,
1976; Hill and Milas, 1989). We employed a different approach
to estimate LSC frequency based on the observations that
single CFCs from the spleens of leukemic mice consistently
induced short-latency AML following transplantation (of single
plucked colonies) into secondary recipients. When this ap-
proach was used, the proportion of cells that fulfilled the criteria
for AML LSCs (i.e., a single cell that can self-renew extensively
and possesses the potential to initiate, sustain, or regenerate262AML) was approximately 26%–30% of the myeloid lineage cells
in the BMs and spleens of mice with AML, substantially higher
than previous estimates of LSC frequencies in human AML.
Conversely, a conventional measure of LSC frequency based
on limit dilution analysis indicated that 0.8% of AML cells (1 in
121) had the operational features of LSCs. Thus, by comparison
with our single colony isolation and transplantation experiments,
limit dilution analysis appeared to underestimate the number
of cells with LSC potential by approximately 30-fold. The differ-
ence strongly suggests that clonogenic LSCs in this model of
AML engraft with low efficiency (estimated to be about 3%),
substantially lower than normal murine HSCs; most studies
concur that HSCs engraft in syngeneic transplant recipients
with approximately 30% efficiency (Camargo et al., 2006). Likely
contributing to this phenomenon, LSCs in our study were mark-
edly inefficient at homing, as indicated by the extremely low per-
centage (0.05%) of secondarily transplanted AML splenocytesCANCER CELL OCTOBER 2006
A R T I C L Epresent in the BM and spleen of syngeneic recipients 24 hr post-
transplant. By comparison, normal murine HSCs typically ex-
hibit 24 hr homing efficiencies of around 10% (Szilvassy et al.,
2003).
Our results are consistent with previous observations sug-
gesting that transplantation assays can significantly under-
estimate the frequency of cancer stem cells. For example, the
number of murine adenocarcinoma cells required to initiate a
subcutaneous tumor was substantially reduced from 6900 to
four (Hewitt et al., 1973) by coinjection of lethally irradiated cells
from the same tumor (presumably containing stromal elements),
suggesting that as many as a quarter of the tumor cells in this
instance have cancer stem cell potential given an appropriate
microenvironment. Thus, in our experiments, LSCs may be rel-
atively deficient in locating supportive niches, by comparison
with normal HSCs, accounting for why many cells with LSC po-
tential failed to read out in a transplant assay. The results of our
studies are therefore most consistent with a high frequency of
LSCs inMLL-AF9 AML that are relatively inefficient in their ability
to home, engraft, and read out in conventional transplantation
assays. Similar interpretations regarding cancer stem cell fre-
quencies in murine tumors have been suggested but not previ-
ously proven (Trott, 1994).
Figure 5. Quantitative transcriptional profiling of MLL-AF9 LSCs and FACS-
sorted normal BM cell subsets
Bar charts show the relative expression levels of the indicated genes in FACS-
sorted normal BM cell subsets, and double-sorted c-kit+ and c-kit2 leukemia
cell populations (upper panel), or IC and LSC populations (lower panel), nor-
malized to Actb expression, using DCt methodology. Error bars for normal
BM populations represent SEMs of three replicate analyses. Error bars for
leukemia cell populations represent SEMs for expression analyses from five
separate leukemic animals (upper panel) and for eight separate paired
populations (lower panel). Transcript levels (lower panel) were further nor-
malized to one another using DCt methodology to show the relative expres-
sion levels of different Hoxa genes. KSL, c-kit+, Sca1+, Lin2; CMP, common
myeloid progenitors; GMP, granulocyte-macrophage progenitors; c-kithi
Mac1+, normal myeloblasts; c-kitlo Mac1+, mostly normal granulocytes
and myelocytes.CANCER CELL OCTOBER 2006The finding of inefficient LSC engraftment and underestima-
tion of LSC frequency in a syngeneic mousemodel has potential
implications for the interpretation of human LSC quantitation
and characterization using NOD/SCID mice. The reported fre-
quency of NOD/SCID leukemia-initiating cells (SL-ICs) in the
blood of humans with AML ranges from 1 in 104 to 1 in 107 (Bon-
net and Dick, 1997). However, as many as one-half of human
AMLs fail to engraft recipient mice at a transplanted dose of
107 cells (Pearce et al., 2006), suggesting the possibility that xe-
nogeneic differences create a high barrier to AML LSC engraft-
ment. Furthermore, the percentage of human cells detected
in the BM of engrafted mice 8 weeks following transplantation
of 107 AML cells is typically remarkably low (median 4%, n =
43) (Ailles et al., 1999). Evidence that conventional NOD/SCID
mouse assays fail to detect at least a proportion of LSCs, due
in part to immunological mechanisms, is further provided by
the observation that 17%–25% of AMLs that fail to engraft in
conventional NOD/SCID mice are able to engraft NOD/SCID
mice, which are additionally deficient for b2-microglobulin (Feur-
ing-Buske et al., 2003; Pearce et al., 2006). Furthermore, the
efficiency of engraftment of normal human HSCs in even the
most permissive immune-deficient mouse model (NOD/SCID
Il2rg 2/2) remains markedly inferior to engraftment efficiencies
observed for normal murine HSCs in syngeneic settings (Bonnet
et al., 1999; Shultz et al., 2005; Camargo et al., 2006). Taken
together, these studies strongly suggest that xenogeneic trans-
plantation approaches are likely to underestimate LSC fre-
quency in human AML analogous to, and perhaps even more
profoundly than, the underestimation observed in our syngeneic
model of AML. Direct evidence that human LSCs might be sig-
nificantly less efficient at engrafting NOD/SCIDmice by compar-
ison with normal HSCs comes from studies of human p210
BCR-ABL acute lymphoblastic leukemia (Castor et al., 2005).
Transplantation of FACS-sorted CD34+, CB382, CD192 cells
from the blood of leukemic patients invariably resulted in exclu-
sively normal human hematopoietic engraftment in NOD/SCID
mice, even though FISH analysis of transplanted cells demon-
strated that >65% were BCR-ABL positive.
MLL-AF9 establishes an AML hierarchy that is outside
and downstream of the normal progenitor compartment
Our studies define the architecture and antigen expression rep-
ertoire of the LSC compartment in a model of human MLL-AF9
AML. The LSC compartment has amaturemyeloid immunophe-
notype, lying almost entirely downstream of the normal BM stem
and progenitor compartment. The hierarchical organization of
murine MLL-AF9 leukemia was loosely defined by c-kit expres-
sion, although a proportion of c-kit-negative cells nevertheless
possessed the ability to induce AML. Expression of Hoxa tran-
scripts was lower in the c-kit2 fraction, and cell cycle inhibitor
transcripts were higher, suggesting the possibility that this pat-
tern of gene expression might be associated with loss of LSC
potential. Expression of Cdk inhibitors has previously been sug-
gested to be inversely associated with self-renewal divisions in
HSCs (Ito et al., 2004; Yuan et al., 2004).
A recent study of murine MLL-AF9 leukemia initiated in GMPs
(Krivtsov et al., 2006) concluded that LSCs were uncommon
cells (approximately 1:150 at late-stage disease) with a Lin2 c-
kit+ phenotype, findings that are in marked contrast to ours.
These differences might be explained by alternative experimen-
tal methodology, for example, the reliance on limit dilution263
A R T I C L EFigure 6. LSCs from mice with MLL-AF9 AML en-
graft with greater efficiency than ICs and possess
altered sensitivities to stromal cell-derived sur-
vival and proliferation signals
A: Limit dilution analyses were performed using
the method of maximum likelihood (Miller and
Eaves, 1997) to determine the number of trans-
planted immortalized cells or leukemic spleno-
cytes required to induce AML in sublethally irradi-
ated syngeneic recipient mice. Between six and
nine mice were transplanted for each indicated
cell dose. Mice were followed for 9 months (left
panel) and 7 months (right panel), and disease
latencies increased with decreasing cell dose
to a maximum of 6 months (left panel) and 14
weeks (right panel). FACS analysis of at least
105 nucleated cells obtained from BM aspirates
(Verlinden et al., 1998) at the end of the follow-
up period confirmed the absence of EGFP+ do-
nor leukemia cells and subclinical disease in
surviving mice. No mice transplanted with 103
or fewer ICs developed AML, whereas all mice
transplanted with 103 leukemic splenocytes
developed AML.
B: Cohorts of mice transplanted with either ICs or
leukemic splenocytes derived from the same
original IC (106 cells/recipient) were euthanized
on the indicated days, and the numbers of
EGFP+ cells in the femurs and spleen were deter-
mined by FACS analysis (mean 6 SEM for three
experiments, two different clones). The calcula-
tions of total EGFP+ cells in the respective ana-
tomic compartments assumed that each femur
contains 7% of the BM of a mouse (Boggs,
1984) and that 70% of cells were recovered
intact following splenic disaggregation or BM
flushing.
C: Bar graph indicates the fold proliferation for ICs or leukemic splenocytes cultured for 4 days in IL-3 or GM-CSF alone (mean6 SEM; n = 8 pairs derived from
the same single cell and representative of 7 separate clones).
D: Bar graph indicates the fold proliferation for ICs or leukemic splenocytes after 14 days culture in liquid medium supplemented with IL-6, IL-11, SCF, or FL alone
(mean6 SEM). The number of leukemic splenocyte populations (out of a total of eight pairs) that acquired the ability to proliferate in the indicated cytokine
alone is shown above the graph.
E: ICs or leukemic splenocytes were cultured in medium with FCS but no growth factors (R10) or medium conditioned by stromal cells (CM), or on a stromal cell
layer (S17 or OP9). Bar graph indicates the fold change in cell number (based on trypan blue exclusion) after 5 days of incubation (mean6 SEM; n = 8 pairs).analysis rather than AML colony analysis for estimating LSC fre-
quency, and different flow cytometry methodology, including
the exclusion of anti-Mac1 from the cocktail of lineage anti-
bodies and the use of an unconjugated anti-Gr1 antibody.
An important question is whether our model accurately re-
flects the cellular organization of human MLL-AF9 AML. Evi-
dence that this is indeed the case is suggested by studies dem-
onstrating that CD342 blood blasts from patients with AML-M5
harboring a t(9;11), the cytogenetic hallmark of an MLL-AF9 fu-
sion gene, were able to engraft NOD/SCID recipients (Blair et al.,
1997; Blair and Sutherland, 2000). This raises the possibility that
human and mouse MLL-AF9 AML share similarities in their hier-
archical organizations outside of the normal progenitor com-
partment. Thus, the observed differences in the architecture of
the leukemia in our model by comparison with that presumed
for the majority of human AMLs, where SL-ICs mostly have a
CD34+ CD382 Lin2 phenotype, may be due at least in part to
oncogene-specific effects, and not fundamental differences in
mouse and human AMLs, or limitations of our experimental
model, which involves the use of a retroviral promoter to drive
expression of MLL-AF9. The hyperexpression of Hox genes
maintained by MLL oncoproteins (Ayton and Cleary, 2001)
may confer specific architectural features on the leukemia cell264hierarchy at a critical stage downstream of the normal progeni-
tor compartment. Our findings therefore suggest that, parti-
cularly in murine models of leukemia, and possibly in human
AML associated with MLL fusion oncogenes, the assumption
that all LSCs reside in the lineage-negative compartment should
be revised. Furthermore, the phenotype of cells targeted for
AML initiation cannot necessarily be deduced by the phenotype
of the LSC. Our studies also raise the possibility that targeting
rare leukemia cells with a stem cell phenotype may not neces-
sarily result in improved therapeutic outcomes for certain types
of AML, since disease relapse may be mediated by more
frequent cells with immunophenotypes that are distinct from
normal HSCs.
The nature of the MLL-AF9 LSC
The immortalized (premouse) and leukemic (postmouse) CFCs
in this model display some features of both stem cells (the bio-
logical property of extensive self-renewal) and differentiated
cells (Sca12 Lin+ immunophenotype). An important question
is whether the CFCs are more akin to HSCs that aberrantly ex-
press myeloid lineage markers due to the leukemogenic event,
or more differentiated cells that have aberrantly acquired
Hoxa-mediated self-renewal. The latter scenario is suggestedCANCER CELL OCTOBER 2006
A R T I C L EFigure 7. Enhanced SDF1 induced chemotaxis
and increased small GTPase expression in MLL-
AF9 LSC populations
A: Bar chart shows mean (6SEM; n = 8 pairs) per-
centage migrations of IC- or LSC-containing
populations in fibronectin-coated Transwell che-
motaxis assays toward a 100 ng/ml SDF1 gradi-
ent (left columns) and mean (6SEM; n = 8 pairs)
adhesion of cells to fibronectin in adhesion as-
says (right columns). Cells did not migrate or
adhere in the absence of SDF1 and fibronectin,
respectively.
B: Bar chart shows mean (6SEM; n = 8 pairs) fluo-
rescent intensity (MFI) of IC- or LSC-containing
populations when analyzed by FACS for surface
Cxcr4 expression. MFI of cell populations stained
with streptavidin-PE alone, and no primary anti-
body, was <20.
C: Bar chart shows mean (6SEM; n = 7 pairs) pro-
tein levels of the indicated small GTPases, nor-
malized to b-actin, as assessed by densitometry
analysis of western blot bands using ImageJ soft-
ware. The panels show western blots of cytoplas-
mic lysates from representative IC and LSC pop-
ulations analyzed for Rac, Cdc42, and b-actin
(top and bottom), and for cellular content of
Rac-GTP and Cdc42-GTP (middle, determined
by PAK1-PBD agarose bead pulldown).by the observed transcriptional and immunophenotypic profiles
of the c-kit+ leukemia cell populations, which are enriched for
LSC activity, by comparison with normal stem and progenitor
cells, and the absence of detectable multilineage differentiation
arising from the LSCs. A somewhat similar conclusion was
reported by Krivtsov et al., (2006). Nevertheless, during the
in vivo progression of immortalized CFCs to fully transformed
LSCs in this model, it is interesting to note that the acquisition
of (1) enhanced engraftment potential, (2) enhanced sensitivity
to stromal cell-derived survival/proliferation signals, and (3) in-
creased SDF1-induced chemotaxis could readily be character-
ized as the acquisition of amore stem-like biological phenotype,
possibly permitting LSCs to take advantage of alternative hema-
topoietic niches to those available to either normal HSCs or
MLL-AF9-immortalized CFCs.
Consistent with the observed enhanced migration and en-
graftment potential of LSC compared with IC populations, and
the critical role of small GTPases in hematopoietic cell migration
and engraftment (Yang et al., 2001; Gu et al., 2003; Cancelas
et al., 2005), we found significantly increased expression levels
of the small GTPase Cdc42 and more variable increases in Rac
expression. Increased small GTPase protein levels were associ-
ated with increased activity. However, it is unlikely that these
findings account for all of the biological differences between
LSC and IC populations, which undoubtedly result from ac-
quired heterogeneous genetic and/or epigenetic changes. This
is suggested, for example, by the finding that the AML cell pop-
ulations in this study displayed a range of cytokine sensitivity
profiles. Furthermore, the observation that direct contact with
stromal cells provided an optimal proliferative stimulus for
LSCs, by comparison with stromal cell-conditioned medium,
suggests that the stromal cell interaction with LSCs is complex,
potentially involving multiple signaling pathways.
Nevertheless, the observation that LSCs consistently dis-
played an enhanced ability to survive/proliferate in contact
with stromal cells by comparison with ICs emphasizes the likely
biological importance of microenvironmental interactions forCANCER CELL OCTOBER 2006MLL-AF9-mediated leukemogenesis. Such interactions are cru-
cial in solid tumors (Hewitt et al., 1973; Bhowmick et al., 2004;
Orimo et al., 2005) and have previously been suggested to be im-
portant in AML (Giles et al., 2002). Although a stepwise progres-
sion in the pathogenesis ofMLL-AF9 leukemiawas reported pre-
viously in a knockin mouse model (Johnson et al., 2003), the
critical biological observation was of progressive temporal in-
creases in the frequency of aberrantly self-renewing stem and
progenitor cells. Conditional activation of MLL-CBP resulted in
increased stem and progenitor cell self-renewal, but this only
induced a mild expansion of the myelomonocytic compartment
(Wang et al., 2005). Uncharacterized secondary genetic and bi-
ological events induced by g-irradiation or N-ethyl-N-nitrosurea
were required to generate fatal myeloproliferative disease. By
contrast, our finding that altered microenvironmental interac-
tions are a consistent feature of LSCs by comparison with ICs
provides important evidence that acquisition of sensitivity to
stromal cell-derived proliferation signals is a critical step in
MLL oncogene-mediated leukemogenesis and warrants further




FVB.Cg-Tg (GFPU) 5Nagy/J and wild-type FVB/NJ mice were purchased
from Jackson Laboratories (Bar Harbor, ME) and maintained on an inbred
FVB background. All experiments on mice in this study were performed
with the approval of and in accordance with Stanford’s Administrative Panel
on Laboratory Animal Care.
Retroviral constructs and BM progenitor cell transduction
A retroviral construct encoding MLL-AF9 was generated by fusion of the car-
boxy-terminal 91 amino acids of human AF9 (accession number BC036089)
in-frame with the amino-terminal 1395 amino acids of human MLL in the
retroviral vector MSCV-50MLL-Neo (DiMartino et al., 2002). Prior to transduc-
tion, BM cells were flushed from the long bones of 4- to 8-week-old mice and
immunomagnetically selected for c-kit expression using phycoerythrin (PE)-
conjugated anti-CD117 (clone 2B8, BD Pharmingen, San Jose, CA), anti-PE265
A R T I C L Emagnetic microbeads (Miltenyi Biotec, Auburn, CA), and an automated cell
separator (AutoMACS, Miltenyi Biotec). c-kit+ stem and progenitor cells
were incubated overnight in RPMI 1640 with 20% fetal calf serum, 20%
WEHI-conditioned medium (R20/20), 20 ng/ml SCF, and 10 ng/ml IL-6
(R&D Systems, Minneapolis, MN) to promote cell cycle entry. Cells were
then spinoculated with retroviral supernatant in the presence of 5 mg/ml poly-
brene for 2 hr at 1350 3 g and 32C. Following spinoculation, cells were
incubated overnight in the above medium to allow for expression of neomy-
cin resistance in transduced cells prior to further manipulation.
In vitro culture of MLL-AF9-transformed progenitor cells
Postspinoculation c-kit+ cells (104) were plated in methylcellulose medium
(M3231, Stem Cell Technologies, Vancouver, BC) containing 20 ng/ml
SCF, 10 ng/ml IL-6, 10 ng/ml GM-CSF, 10 ng/ml IL-3 (R&D Systems), and
G418 (0.75 mg/ml) (Gibco, Carlsbad, CA). After 5 days of culture, colonies
were counted and pooled, and then 104 cells were replated in the same me-
dium but without G418. For the third round of culture, 5 3 103 cells were
plated. At the end of the third round (or after one round of culture in the
case of colonies derived from leukemic splenocytes), single colonies were
plucked from methylcellulose and transferred to liquid culture initially in sin-
gle wells in 96-well plates containing R20/20, 20 ng/ml SCF, and 10 ng/ml IL-
6. Cultures derived from single colonies were subsequently transferred to
6-well plates on day 4 of culture, and the medium was changed every 5
days thereafter. Once individual cultures had expanded beyond 106 cells,
they were maintained solely in R20/20. For colony assays of transplanted
immortalized progenitor cells or leukemic splenocytes (sorted and unsorted),
2–5 3 103 cells were plated in methylcellulose medium with the above four
growth factors but without G418.
For studies involving culture of cells in medium containing single growth
factors, immortalized progenitor cells or cells derived from leukemic sple-
nocytes (cultured in R20/20 for 6–19 days) were washed three times in
RPMI 1640 and then plated at a concentration of 2 3 105/ml in medium
containing RPMI 1640 with 20% fetal calf serum and either 20 ng/ml IL-3,
20 ng/ml GM-CSF, 20 ng/ml IL-6, 20 ng/ml SCF, 10 ng/ml human IL-11
(Peprotech, Rocky Hill, NJ), or 10 ng/ml human Flt3 ligand (R&D Systems).
Viable cell counts using trypan blue dye exclusion were performed every
2–4 days, and medium was replaced when cultures were split, or every
4 days.
For studies involving stromal cell coculture, immortalized progenitor cells
or cells derived from leukemic splenocytes (as above) were washed three
times in RPMI 1640, and then 2 3 105 cells were added to either a confluent
layer of stromal cells in one well of a 12-well plate containing 2 ml of medium,
medium only, or stromal layer-conditioned medium. Either S17 stromal cells
(cultured in RPMI 1640 with 10% fetal calf serum) (Collins and Dorshkind,
1987) or OP9 stromal cells (cultured in MEM awith 10% fetal calf serum) (Ko-
dama et al., 1994) were used. Stromal layer-conditioned medium was made
by combining medium harvested following 48 hr contact with the stromal
layer with fresh medium in a 1:1 ratio. Following culture for 5 days, with me-
dium being 50% replaced every 2 days, the number of viable hematopoietic
cells was determined using trypan blue exclusion, following trypsinization in
the case of the cells cultured on stromal layers. Hematopoietic cells were
readily distinguished from stromal cells by both a marked difference in size
and their green fluorescence.
Transplantation procedures, homing, and engraftment studies
Transplantation of immortalized cells, or secondary and tertiary transplanta-
tion of cells derived from leukemic animals, was performed by retro-orbital
injection of sublethally irradiated syngeneic FVB mice (450 cGy). When c-
kit+ stem and progenitor cells were transplanted immediately following retro-
viral transduction (C57BL/6 background), mice were lethally irradiated (900
cGy), and 300,000 postspinoculation cells (representing 3600 transduced
CFUs; CFU transduction efficiency 35%) were injected, together with
250,000 nucleated BM cells as radioprotection. When transplanted mice ex-
hibited signs of ill health, they were euthanized. For homing and engraftment
studies, cohorts of mice were transplanted with 106 EGFP+ cells each, and
then one mouse from each cohort was euthanized on days 1, 2, 4, 8, and
20 posttransplant. The BM was then flushed from both femurs, the spleen
was disaggregated, and following red cell lysis, the numbers of EGFP+ cells
in the marrow and spleen were determined by flow cytometry.266Flow cytometry
Staining of cells for FACS analysis and sorting was performed using the fol-
lowing conjugated antibodies obtained from either BD Pharmingen (BD) or
eBioscience (eB) (San Diego, CA), except where indicated, at a dilution of
1:100 in PBS containing 2% fetal calf serum and 2 mM EDTA (staining me-
dium) for 20 min on ice: Mac1-PE (eB) or Cy7APC (BD) (clone M1/70), Gr1-
PE (clone RB6-8C5, eB), c-kit-APC (clone 2B8, eB), Sca1-Cy5PE (eB) or
FITC (BD) (clone D7), CD16/32-Cy7PE (clone 93, eB), Flt3-PE (clone AF2
10.1, BD), F4/80-PE (Caltag Laboratories, Burlingame, CA), biotinylated
CD31 (clone 390, eB), biotinylated CD24 (clone 30-F1, BD), biotinylated or
FITC-conjugated CD34 (1/20) (clone RAM34, BD), biotinylated Cxcr4 (clone
2B11, BD), streptavidin-conjugated Cy7PE (eB), or PE (BD) (1/400). To stain
lineage-positive cells, a cocktail of the following PE-conjugated antibodies
was used: Mac1, Gr1, B220 (clone RA3-6B2, BD), TER119 (clone TER-119,
eB), CD3 (clone 145-2C11, BD), CD4 (clone RM4-5, BD), CD8 (clone53-
6.7, eB). Normal progenitor cell populations were isolated by FACS sorting
for the following immunophenotype (C57BL/6 mice used as donors): KSL,
c-kit+, Sca1+, Lin2; CMP, c-kit+, Sca12, Lin2, CD34+, CD16/32lo; GMP, c-
kit+, Sca12, Lin2, CD34+, CD16/32hi; myeloblasts, c-kithi, Mac1+; granulo-
cytes/myelocytes, c-kitlo/2 Mac1+. Following staining, cells were washed
once in staining medium and then analyzed using an LSR Model 1a flow cy-
tometer (BD Biosciences, San Jose, CA). Some analyses and all cell sorts
were performed using a dual laser FACS Vantage (BD Biosciences).
Real-time quantitative PCR analysis of gene expression
RNA from sorted cell populations was purified using Trizol, and 0.5 mg was
reverse transcribed using an oligo-dT primer and Superscript First-Strand
Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. The reaction products were diluted in TE, and
2 ml was subjected to real-time PCR, which was performed in triplicate using
Taqman probes and the ABI Prism 7700 sequence detection system.
Taqman probes for Hoxa5 (Mm00439362_m1), Hoxa7 (Mm00657963_m1),
Hoxa9 (Mm00439364_m1), Hoxa10 (Mm00433966_m1), Hoxa11
(Mm00439360_m1), Meis1 (Mm00487664_m1), Cdkn1b (Mm00438167_g1),
Cdkn2a (Mm00494449_m1), Cdkn2c (Mm00483243_m1), Flt3
(Mm00438996_m1), Mpl (Mm00440310_m1), Ela2 (Mm00469310_m1),
Prtn3 (Mm00478323_m1), Gstm2 (Mm00725711_s1), and b-Actin
(Mm00607939_m1) were purchased from Applied Biosystems (Foster City,
CA). Expression levels of analyzed genes relative to that of b-Actin were
calculated using the comparative Ct method, as described in ABI User
Bulletin #2.
Transwell migration and adhesion assays, and GTPase
expression and activity analyses
Cell migration assays were performed using fibronectin-coated Transwell
polycarbonate membranes (5 mm pore size) in 24-well plates (Corning, Corn-
ing, NY). 2 3 105 cells, suspended in R20/20, were placed in the insert and
allowed to migrate for 8 hr along a Cxcl12 (SDF1, Peprotech) gradient, cre-
ated by addition of 100 nM Cxcl12 to R20/20 medium beneath the mem-
brane. For adhesion assays, 53 105 cells suspended in R20/20 were placed
in fibronectin-coated and BSA-blocked 12-well tissue culture plates for 1 hr
to permit adhesion. Nonadherent cells were removed by gently adding, and
then tipping out, PBS to the wells three times. Adherent cells were then
trypsinized and counted.
Cdc42 and Rac GTPase activity assays, and western blot analyses, were
performed using commercially prepared reagents according to themanufac-
turer’s instructions (Cell Biolabs, San Diego, CA). Anti-actin (mouse mono-
clonal C4) was from Chemicon International (Temecula, CA).
Supplemental data
The Supplemental Data include two supplemental tables and can be found
with this article online at http://www.cancercell.org/cgi/content/full/10/4/
257/DC1/.
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